FDA Approves Abbott’s Spinal Cord Stimulation System for Diabetic Peripheral Neuropathy

The FDA has approved Abbott’s Proclaim XR spinal cord stimulation system to treat patients with diabetic peripheral neuropathy, a complication of diabetes that results in pain and numbness in legs, hands, and feet.

The system, which delivers low amounts of electrical stimulation, uses a battery that can last up to 10 years at low-dose settings and is controlled through the company’s NeuroSphere Virtual Clinic app. The app connects patients to physicians and adjusts treatments remotely through an Apple device.

The Proclaim XR system was previously approved in 2019 to treat chronic pain.